As with other new procedures, as discussed above, we have identified a potentially dangerous issue associated with the Coblation device intraoperatively. Specifically, there are two settings used during surgery. The Coblation mode is for the volumetric removal of target tissue with precise plasma energy, while the coagulation mode is designed for hemostasis. These settings are selected via a double-switch foot pedal. The two switches are indistinguishable from each other by touch-other than their position on the pedal assembly. During surgery, if Coblation is inadvertently activated instead of coagulation , a rapid, deep penetration into the tonsil fossa tissue may ensue.
We analyzed this problem and have developed a simple solution, dubbed the 'Blation Bounce (figure) . We 852· www.entj o urnal.com removed the bulb from an irrigation syringe and cut it in half with heavy scissors. We then attached this piece to the Coblation pedal with tape and Coban wrap (3M Corp.; St. Paul, Minn.) . This adaptation provides a tactile difference between the two pedals . Further, it gives a "bounce" to the pedal, so that the switch is on ly activated with firmer foot pressure.
Another safety step is to always activate the device prior to touching any tissue.
Whi le not studied in a scientific manner, we believe that this modification has the potential to reduce inadvertent injury to patients. ,.
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- Pregnancy T e~a t o g e n i c Effects. Pregnancy CategoryC: Reproduction studieshave been performed in rats and mice usmq oral doses of upto 100 mg/kg andIV doses up to 30mg/kg andhaverevealed noevidenceof harm to the fetus as a result of ciprofloxacin. In rabbits, ciprofloxacin (30 and 10 0 mg/kg orally) produced gastrointestinal disturbances resulting In maternal weight loss and an increased incidence of abortio n, but no teratogenicity~as observed at eitherdose..After intravenous administrat ion of doses up to 20 mg/kg, no rnaternaltoxlcity was produced Inthe rabbit, and no e. mbryotoxicity or teratogenicity was observed. Corticosteroidsare generallyteratogemc In laboratory anima ls when administered systemicallyat relativelvlow dosage levels.The more potent corticosteroidshave beenshownto be teratogenic after dermal applicationin laboratoryanimals. Ani mal reproduction studieshave not been conductedwithC I P RO D EXÕ t ic. Noadequateand wellcontrolled studieshave been performed in pregnant women. Caution should be exercisedwhen C IPROOE X~O tic is used by a pregnantwoman.
Nursing Mothers: C i pr o f l ox a~i n and corticosteroids,as a.class,appear in mil kfollowing oraladministration. Dexamethasone In breast mi lk could suppress growth, InterfereWith endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical otic administration of ciprofloxac in or dexamethasone could result in sufficient systemic absorption to produce detectable quantities in human milk. Because of the potential for unwanted effectsin nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, takingintoaccount the importa nce of the drug to the mother. Pediatric Use: The safety and efficacy of C I P R O OEX~O tic havebeen established in pediatric patients 6monthsandolder (937patients)in adequate andwell-controlledclinical trials. Although nodataareavailable on patients less than age 6 months, there are no known safetyconcerns or differences inthe disease process inthispopulationthat would precludeuseofthis product. (See DOSAGEANDADMINISTRATION.) Noclinicallyrelevantchanges inhearingfunction wereobserved in 69pediatric patients(age4to 12years l treated with C IPROOE X~Ot ic and tested for audiometric parameters.
ADVERSEREACTIONS
In Phases II and III clinical trials, a total of 937 patientsweretreated with C IPR OOE X~Otic. This included 400patients with acute otitismedia with tympan ostomytubesand 537patients with acute otitis exlerna.
The reported treatment-relat ed adverse events are listed below:
Acute Otitis Media in pediat ric patients with tympanostomy tubes: The following treatment ·related adverse events occurred in 0.5% or more of the patients withnon-intact tympanic membra nes.
The following treatment-related adverse events were each reported in a single patient ear discomfo rt; broad-spectrum antibacterial agent, ciprofloxacin hydrochlorid e, combined with the anti·infla mmatory corticosteroid, dexamethasone, in a sterile, preserved suspensi on for otic use. Each mL of CIPRODEX<!l Ot ic contains ciprofloxacin hydrochloride (equivalentto 3 mg ciprofloxacin base), 1 mg dexamethasone, and 0.1 mg benzalkonium chloride as a preservative. The inactive ingredientsare bori c acid,sodiumchloride, hydroxyethyl cellul ose,tyloxapol, acetic acid, sodiumacetate, edetate disodium, and purifiedwater. Sodium hydroxideor hydrochloric acid may beadded for adjustment of pH. Ciprofloxacin, a f1uoroquinolone is avail abl e as the monohydrochloride monohydrate salt of r-evelopropyl-6-f1uoro·l ,4-dihydro-4-oxo-7-(1 -piperazinyl)-3-quinolinecarboxylic acid. The empirical formula is C17HI 8FN303·HCI ·H20. Dexamethasone, 9-fluoro-l l (beta),17,21 -trihydroxy-16(alphal-methylpregna-l , 4-diene-3,20-dione, is an anti-Inflammatorycorticosteroid.The empirical formula is C22H29F05. CLINICALPHARMACOLOGY Pharmacokinetics: Foll owinga single bilateral4-drop(total dose = 0.28 mL, 0.84mg ciprofloxacin, 0.28 mg dexamethasone)topical otic dose of C IPROOEX~Ot ic to pediatric patient s after tympanostomy tube insertion, measurable plasma concentrati ons of ciprofloxacin and dexamethasone were observe d at 6 hours followingadministration in 2of 9 pat ients and 5 of 9 pati ents,respectivel y. Mean ± SO peak plasma concentrations of ciprofloxaci n were 1. 39 ± 0.880 ng/mL (n=9). Peak plasma concentrations ranged from 0.543 ng/mL to 3.45 ng/mL and were on average approximately 0.1 % of peak plasma concentrations achieved with an oral dose of 250-mg1 3 1, Peak plasma concentrations of ciprofloxacinwere observedwithin 15minutes to 2 hours post dose application. Mean ± SOpeak plasma concentrationsof dexamethasone were 1.14 ± 1.54 ng/mL(n=9). Peak plasma concentrations ranged from 0.1 35 ng/mL to 5.10 ng/mL and were on average approxi mately 14% of peak concentrations reported in CONTRAINDICATIONS C IPROOEX~Otic is contraindicated in patients with a history of hypersensitivi ty to ciprofloxacin, to other quinolones, or to any of the components in this medication. Use of this product is contraindicatedinviral infections ofthe external canal including herpes simplexinfections.
WARNING S FOR OT ICUSE ONLY (This product is not approvedfor ophthalmicuse.l NOTFOR INJECTION
C IPROOE X~Ot ic should be discont inuedat the first appearance of a skin rash or any other sign of hypersensitivi ty. Serious and occas ionally fatal hypersensitivity (anaphylacticl reactions, some following the first dose, have been reported in patients receiving systemic quin olones. Serious acute hypersensitivity reactions may require immediate emergencytreatment.
PRECAUTIONS
General: Aswith other antibacterial preparations, use ofthis product may resultin overgrowth of nonsusceptible organisms, including yeast and fungi. Ifthe infectionis not improved after one week of treatment, culturesshould beobtai nedto guidefurthertreatment. If otorrhea persists after a full courseofl herapy,or iftwo or more episodes of otorrheaoccur within sixmonths, further evaluationis recommendedto exclude an underlying condition such as cholesteatoma,foreign body, or a tumor. The systemic admi nistration of quinolones, including ciprofloxacin at doses much higher than given or absorbed by the otic route, has led to lesions or erosions of the cartilage in weight-bearing joints and other signs of arthropat hy in immature animals of various species. Guinea pigsdosed in the middle earwith CIPROOE X~Otic for one month exhibited no drug-related structural or functi onal changes of the cochlear hair cellsand no lesions in the ossicles. CIPROD EX~Oti c was also shown to lack dermalsensitizing potential in the guinea pig whentested accordingtothe method of Buehl er. No signs of local irritationwere found whenC IPROOE XÕ tic was applied topically in therabbi t eye. Information for Patients: For otic use only. (Thi s product is not approved for use in the eye.l Warmthe bottl e inyour handfor one to two mi nutes pri or to use and shake well immediately before using. Avoid contami nating the tip with material from the ear, fingers, or other sources. Protect from light. If rash or allergic reaction occurs, discontinue use immediatelyand contact your physician. It is veryimportant to use the ear drops for as long as the doctor has instructed, even if the symptoms improve. Di scard unused porti onaftertherapy is completed. AcuteOtitis Mediain pediatric patients with tympanostomy tubes : Priorto administ ration of CIPROO EX~Otic in pat ients (6 months and older) with acute otitis media through tympanostomytubes, the solution should be warmed by holding Alcon LETIE RS TO THE EDITOR ed to p ublish th e result s, I would have to go th rou gh an IRB, and th at th e IRB would want signed con sents from all th e pati ent s whose de-identi fied data I used.
Non e of the three community hospit als where I wor k has an IRB, so I first would have had to set up th e IRB. Being in private practice, I found th ose requirem ent s overwhelm ing, and so I did not wr ite the paper from th e data I had analyzed.
I also had th ou ghts of wri ting ot her papers with th e data I had on th e computer for my allergy patients, but with more th an 2,200 patient s to contact to ask if I might use their de-id entified data, that idea was completely derailed.
Th ank you for your very insight ful editorial. I trust th at it will stimulate discussion and brin g th e needed changes to HI PAA rul es.
